πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 2,432 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11439611

Administration of serine protease inhibitors to the stomach

The Regents of the University of California Β· Granted Tue Sep 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11432547

Inhibitors of GRB2-associated binding protein 1 (GAB1) and methods of treating cancer usin

Arizona Board of Regents on Behalf of the University of Arizona Β· Granted Tue Sep 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11433118

Long-acting VEGF inhibitors for intraocular neovascularization

The Regents of the University of California Β· Granted Tue Sep 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11434233

Heterocyclic inhibitors of ATR kinase

The Board of Regents of the University of Texas System Β· Granted Tue Sep 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11426420

Inhibitors of short-chain dehydrogenase activity for treating coronary disorders

The Board of Regents of the University of Texas System Β· Granted Tue Aug 30 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11426393

Prolyl hydroxylase inhibitors and methods of use

Akebia Therapeutics, Inc. Β· Granted Tue Aug 30 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11420936

Hypoxia inducible factor-2(alpha) inhibitors and their use in the treatment of diseases

NIKANG THERAPEUTICS, INC. Β· Granted Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11414379

SPAK kinase inhibitors as neuroprotective agents

United States Government as represented by the Department of Veterans Affairs Β· Granted Tue Aug 16 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 11 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11407723

Selective histone deacetylase inhibitors for the treatment of human disease

Shuttle Pharmaceuticals, Inc. Β· Granted Tue Aug 09 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11407712

Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2Ξ±

Arcus Biosciences, Inc. Β· Granted Tue Aug 09 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11401246

Triazole glycolate oxidase inhibitors

Century Therapeutics, Inc. Β· Granted Tue Aug 02 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11401286

Heteroaryl inhibitors of PDE4

Tetra Discovery Partners Β· Granted Tue Aug 02 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11390646

Structure-based peptide inhibitors of Ξ±-synuclein aggregation

The Regents of the University of California Β· Granted Tue Jul 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11390631

Benzodiazepine derivatives as RSV inhibitors

Enanta Pharmaceuticals, Inc. Β· Granted Tue Jul 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11382955

Long-acting VEGF inhibitors for intraocular neovascularization

The Regents of the University of California Β· Granted Tue Jul 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11384055

Glycolate oxidase inhibitors for the treatment of disease

BIOMARIN PHARMACEUTICAL INC. Β· Granted Tue Jul 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11384076

Synthesis, pharmacology and use of new and selective FMS-like tyrosine kinase 3 (FLT3) FLT

UniversitΓ€t Regensburg Β· Granted Tue Jul 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11377469

CD73 inhibitors

ORIC PHARMACEUTICALS, INC. Β· Granted Tue Jul 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 30 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11376247

Tyrosine kinase inhibitors regenerate non-cancerous tissue after cancer therapy

The Regents of the University of Colorado, a Body Corporate Β· Granted Tue Jul 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 30 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11377444

Pyridopyrimidine compounds acting as mTORC 1/2 dual inhibitors

Medshine Discovery Inc. Β· Granted Tue Jul 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 30 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11370798

Compounds useful as inhibitors of ATR kinase

Vertex Pharmaceuticals Incorporated Β· Granted Tue Jun 28 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11370774

Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement

BioCryst Pharmaceuticals, Inc. Β· Granted Tue Jun 28 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11370786

GLS1 inhibitors for treating disease

The Board of Regents of the University of Texas System Β· Granted Tue Jun 28 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11370803

Heteroaryl plasma kallikrein inhibitors

Takeda Pharmaceutical Company Limited Β· Granted Tue Jun 28 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted